Journal of International Psychiatry

Abstract】Objective To explore effect of paliperidone on quality of life. Methods 98 patients with schizophreniainto study group（paliperidone）andcontrol group（olanzapine），studygroupweregivenpaliperidonefor threedays， （paliperidone）andcontrol group（olanzapine），studygroupweregivenpaliperidonefor threedays， paliperidone）andcontrol group（olanzapine），studygroupweregivenpaliperidonefor threedays， ）andcontrol group（olanzapine），studygroupweregivenpaliperidonefor threedays， and control group（olanzapine），studygroupweregivenpaliperidonefor threedays， （olanzapine），studygroupweregivenpaliperidonefor threedays， olanzapine），studygroupweregivenpaliperidonefor threedays， ），studygroupweregivenpaliperidonefor threedays， study group were given paliperidone for three days，were injected 150mg paliperidone without allergic reaction，thengiven100mginjectionat intervalsof 8days，injected ，thengiven100mginjectionat intervalsof 8days，injected then given 100mg injection at intervals of 8 days，injected ，injected injected75 mg ~ 150 mg monthly. Control group were given 5mg to 30mg orally olanzapine，psychiatricsymptomsandthera- ，psychiatricsymptomsandthera- psychiatric symptoms and thera-peutic effect were assessed by the Positive and Negative Syndrome scale（PANSS）andClinicalGlobalImpressionScale （PANSS）andClinicalGlobalImpressionScale PANSS）andClinicalGlobalImpressionScale ）andClinicalGlobalImpressionScale and Clinical Global Impression Scale（CGI）beforeandaftertreatment inthe4 CGI）beforeandaftertreatment inthe4 ）beforeandaftertreatment inthe4 before and after treatment in the 4th，8th，12 12th，16 16thweek. Quality of life and satisfaction were evaluated byQuality of Life Enjoyment and Satisfaction Questionnaire（Q-LES-Q），adversereactionswereevaluatedbytreatment （Q-LES-Q），adversereactionswereevaluatedbytreatment Q-LES-Q），adversereactionswereevaluatedbytreatment ），adversereactionswereevaluatedbytreatment adverse reactions were evaluated by treatmentemergent symptom scale（TESS）；safetywas evaluatedbylaboratorytests，bloodbiochemistry，bodymass. （TESS）；safetywas evaluatedbylaboratorytests，bloodbiochemistry，bodymass. TESS）；safetywas evaluatedbylaboratorytests，bloodbiochemistry，bodymass. ）；safetywas evaluatedbylaboratorytests，bloodbiochemistry，bodymass. safety was evaluated by laboratory tests，bloodbiochemistry，bodymass. ，bloodbiochemistry，bodymass. blood biochemistry，bodymass. ，bodymass. body mass. Results The differences of the PANSS，CGIscoresat eachtimepoint weresignificant beforeandaftertreatment ，CGIscoresat eachtimepoint weresignificant beforeandaftertreatment CGI scores at each time point were significant before and after treatment P <0.05或P <0.01），wasnot significant betweenthetwogroups（ ），wasnot significant betweenthetwogroups（ was not significant between the two groups（P >0.05）.Thedifferencesof Q-LES-Qscoresweresignificant ）.Thedifferencesof Q-LES-Qscoresweresignificant .The differences of Q-LES-Q scores were significantafter treatment（P <0.05或 P <0.01），laboratorytests，bloodbiochemistrydidnot changesignificantly，weight mass ），laboratorytests，bloodbiochemistrydidnot changesignificantly，weight mass laboratory tests，bloodbiochemistrydidnot changesignificantly，weight mass ，bloodbiochemistrydidnot changesignificantly，weight mass blood biochemistry did not change significantly，weight mass ，weight mass weight massand prolactin levels were increased after treatment. Conclusion The efficacy and side effects of paliperidone in patientswith schizophrenia，wereequal toolanzapine；lessinfluenceonbodymassandprolactinlevelsthanolanzapine，were ，wereequal toolanzapine；lessinfluenceonbodymassandprolactinlevelsthanolanzapine，were were equal to olanzapine；lessinfluenceonbodymassandprolactinlevelsthanolanzapine，were ；lessinfluenceonbodymassandprolactinlevelsthanolanzapine，were less influence on body mass and prolactin levels than olanzapine，were ，were wereprior to olanzapine on quality of life and satisfaction.

Paliperidone palmitate；Schizophrenia；QualityofLife ；